Apollomics, Inc. (APLM)
Develops cancer-fighting drugs that boost the immune system and target specific tumor mutations.
$18.22+0.01%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+210.4%
The outlook
APLM is trading above both its 50- and 200-day moving averages, positioning it in the upper portion of its recent range. The stock sits about 38% of the way between its 52-week low and high. Analyst coverage appears thin, and the overall data leans bullish based on current technical positioning.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range38% of the way from its 52-week low to high
Market cap
$40.0M
52-wk high
$42.12
52-wk low
$3.66
50-day avg
$16.83
200-day avg
$17.74
Trailing P/E
—